Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Boehringer Ingelheim Fremont, Inc.
EIR
•Boehringer Ingelheim Fremont, Inc.•April 13, 2023

Boehringer Ingelheim Fremont, Inc. – FDA EIR, Apr 13, 2023

Record Details

The FDA conducted a routine pre-approval inspection of Boehringer Ingelheim Fremont, Inc. from April 11-13, 2023, in Fremont, CA. This inspection, conducted under Compliance Program 7346.832 for Pre-Approval Inspections, specifically focused on the Injectable Delivery Device component of their Cyltezo (adalimumab-adbm) Autoinjector, 40 mg/0.8 mL, for Biologics License Application 761058/Supplement 16. The regulatory framework also referenced compliance programs for combination products and licensed biological therapeutic drug products, operating under the broader oversight of the FD&C Act.

During this recent inspection, FDA investigators reviewed various documents, including process validation, commercial batch records, deviation logs, and calibration records. Notably, no significant objectionable conditions were identified. This finding contrasts with a previous FDA inspection conducted from October 25 to November 4, 2022, which resulted in a "Voluntary Action Indicated" (VAI) classification. That prior inspection yielded a Form FDA 483 observation regarding the firm's quality control unit, specifically that its responsibilities and procedures were not adequately documented or followed. Although seven additional items were discussed during the closeout of the previous inspection, their corrections were not re-evaluated during the current pre-approval inspection.

The company manufactures and packages its own Cyltezo products and also contract manufactures Keytruda (pembrolizumab) bulk drug substance. The absence of significant issues in this latest inspection suggests a positive status for the specific pre-approval scope, with no new required actions identified. No samples were collected, and no refusals or recalls were reported.

Company
Boehringer Ingelheim Fremont, Inc.
Inspection date
April 13, 2023
Product type
biologics
Office
Division of Pharmaceutical Quality Operations IV
People
  • Nicholas L. Hunt (Senior CSO, Investigator)
  • Dogbeda F. Mackenzie
  • Sara H. Gabel
View Company Profile

ID · 66f1beae-6b38-4ab2-b49c-b4e935efddf3

Other documents for Boehringer Ingelheim Fremont, Inc.
  • 483 - 2022-11-04November 4, 2022
  • EIR - 2022-11-04November 4, 2022
  • 483 - 2018-08-24August 24, 2018
  • 483 - 2017-04-04April 4, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Boehringer Ingelheim Fremont, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.